Quoc Dinh Nguyen

Dr. Quoc Dinh Nguyen

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2014 in Medical Education
Verified
Journal Article
Closed access
PDF file
QNQuoc Dinh Nguyen
Quoc Dinh Nguyen
NFNicolas Fernandez
Nicolas Fernandez
TKThierry Karsenti
Thierry Karsenti
BCBernard Charlin
Bernard Charlin

5 November 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
QNQuoc Dinh Nguyen
Quoc Dinh Nguyen
EMErica M. Moodie
Erica M. Moodie
MFMarie‐France Forget
Marie‐France Forget
PDPhilippe Desmarais
Philippe Desmarais
MKMark R. Keezer
Mark R. Keezer
CWChristina Wolfson
Christina Wolfson

31 August 2018 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
PDF file
QNQuoc Dinh Nguyen
Quoc Dinh Nguyen
CWChenkai Wu
Chenkai Wu
MOMichelle C Odden
Michelle C Odden
DKDae Hyun Kim
Dae Hyun Kim
Background: Frailty and multimorbidity are independent prognostic factors for mortality, but their interaction has not been fully explored. We investigated the importance of multimorbidity patterns in older adults with the same level of frailty phenotype. Methods: In a cohort of 7,197 community-dwelling adults aged 65 years and older, physical frailty status (robust, pre-frail, frail) was defined using shrinking, exhaustion, inactivity, slowness, and weakness. Latent class analysis was used to identify individuals with multimorbidity patterns based on 10 self-reported chronic conditions. We estimated hazard ratios (HR) and incidence rate differences (IRDs) for mortality comparing multimorbidity patterns within each frailty state. Results: Five multimorbidity classes were identified: minimal disease (24.7%), cardiovascular disease (29.0%), osteoarticular disease (27.3%), neuropsychiatric disease (8.9%), and high multisystem morbidity (10.0%). Within each frailty state, the mortality rate per 1,000 person-years over 4 years was greatest in the neuropsychiatric class and lowest in the minimal disease class: robust (56.3 vs 15.7; HR, 2.11 [95% CI: 1.05, 4.21]; IRD, 24.1 [95% CI: −11.2, 59.3]), pre-frail (85.3 vs 40.4; HR, 1.74 [95% CI: 1.28, 2.37]; IRD, 27.1 [95% CI: 7.6, 46.7]), and frail (218.1 vs 96.4; HR, 2.05 [95% CI: 1.36, 3.10]; IRD, 108.4 [95% CI: 65.0, 151.9]). Although HRs did not vary widely by frailty, the excess number of deaths, as reflected by IRDs, increased with greater frailty level. Conclusions: Considering both multimorbidity patterns and frailty is important for identifying older adults at greater risk of mortality. Of the five patterns identified, the neuropsychiatric class was associated with lower survival across all frailty levels.

1 June 2018 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
QNQuoc Dinh Nguyen
Quoc Dinh Nguyen
EPEric Peters
Eric Peters
AWAndreanne Wassef
Andreanne Wassef
PDPhilippe Desmarais
Philippe Desmarais
DRDelphine Rémillard-Labrosse
Delphine Rémillard-Labrosse
MTMaxime Tremblay-Gravel
Maxime Tremblay-Gravel
Background: Older adults and women have historically been underrepresented in randomized controlled trials of cardiology. Recent temporal evolution and factors influencing representation are incompletely investigated. We aimed to contrast age and female representation in the most influential randomized controlled trials in cardiology of the last 20 years to population prevalence and to assess the study factors affecting representation. Methods and Results: Using Web of Science, we selected the 25 most-cited cardiology articles each year between 1996 and 2015, and extracted mean age, percentage of women, funding source, sample size, disease condition, intervention type, and exclusion criteria. The outcomes were the evolution of the mean age and the percentage of women over time. Protocol design elements and year of publication were assessed as predictors of outcomes in multivariable regressions. A total of 500 studies were analyzed, where the mean age was 62.6±7.4 years and the median percentage of women was 28.6% (22.2–40.5). Compared with population prevalence derived from National Health and Nutrition Examination Survey 2015–2016, gaps in representation were apparent and more pronounced for coronary artery disease (−5.0 years; −27.2% women) and heart failure (−6.0 years; −25.4% women). The mean age (0.15 year per year; 95% confidence interval, 0.04–0.26) and percentage of women (+0.29% per year; 95% confidence interval, 0.07–0.50), slightly but significantly increased over time. Private funding, small sample size, and exclusions pertaining to maximal age, atrial fibrillation, and diabetes mellitus were associated with a decreased mean age in multivariable linear regressions. Age and life expectancy exclusions were associated with lower female percentage. Conclusions: Although age and female representation increased over time, the modest trends are unlikely to resolve the persistently wide gaps with actual populational prevalence, especially for coronary artery disease and HF. Representation is modulated by the cardiovascular condition studied and some modifiable protocol elements.

15 September 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
QNQuoc Dinh Nguyen
Quoc Dinh Nguyen
MOMichelle C. Odden
Michelle C. Odden
CPCarmen A. Peralta
Carmen A. Peralta
DKDae Hyun Kim
Dae Hyun Kim
Background: Assessment of atherosclerotic cardiovascular disease (ASCVD) risk is crucial for prevention and management, but the performance of the pooled cohort equations in older adults with frailty and multimorbidity is unknown. We evaluated the pooled cohort equations in these subgroups and the impact of competing risks. Methods and Results: In 4249 community‐dwelling adults, aged ≥65 years, from the CHS (Cardiovascular Health Study), we calculated 10‐year risk of hard ASCVD. Frailty was determined using the Fried phenotype. Latent class analysis was used to identify individuals with multimorbidity patterns using chronic conditions. We assessed discrimination using the C‐statistic and calibration by comparing predicted ASCVD risks with estimated risk using cause‐specific and cumulative incidence models, by multimorbidity patterns and frailty status. A total of 917 (21.6%) participants had an ASCVD event, and 706 (16.6%) had a competing event of death. C‐statistic was 0.68 in men and 0.69 in women; calibration was good when compared with cause‐specific and cumulative incidence estimated risks (males, −0.1% and 3.3%; females, 0.6% and 1.4%). Latent class analysis identified 4 patterns: minimal disease, cardiometabolic, low cognition, musculoskeletal‐lung depression. In the cardiometabolic pattern, ASCVD risk was overpredicted compared with cumulative incidence risk in men (7.4%) and women (6.8%). Risk was underpredicted in men (−10.7%) and women (−8.2%) with frailty compared with cause‐specific risk. Miscalibration occurred mostly at high predicted risk ranges. Conclusions: ASCVD prediction was good in this cohort of adults aged ≥65 years. Although calibration varied by multimorbidity patterns, frailty, and competing risks, miscalibration was mostly present at high predicted risk ranges and thus less likely to alter decision making for primary prevention therapy.

3 March 2025 in Age and Ageing
Verified
Journal Article
Closed access
PNPatrick V-Q Nguyen
Patrick V-Q Nguyen
TDThien T Dang-Vu
Thien T Dang-Vu
GFGeneviève Forest
Geneviève Forest
SDSophie Desjardins
Sophie Desjardins
MFMarie-France Forget
Marie-France Forget
PDPhilippe Desmarais
Philippe Desmarais
Background: Mirtazapine promotes sleep by blocking serotonin and histaminergic receptors and is often used off-label to treat chronic insomnia. However, its efficacy remains to be demonstrated in a clinical trial. The MIRAGE study aims to determine the efficacy and safety of mirtazapine in older patients with chronic insomnia. Methods: This was a double-blind, randomised, placebo-controlled trial in a geriatric outpatient clinic of a teaching hospital. Adults aged 65 years and older with chronic insomnia were included. Sixty participants were randomised in a 1:1 ratio to receive mirtazapine 7.5 mg or a matching placebo for 28 days. The primary efficacy endpoint was the mean change in the Insomnia Severity Index (ISI) score from baseline to 28 days post-treatment. The primary safety endpoints included any adverse events reported during the clinical trial and all adverse events leading to premature discontinuation. Results: Mirtazapine was superior to placebo on the primary outcome measure, subjective wake after sleep onset, total sleep time and sleep efficiency. After 28 days, the mean change in ISI score was significantly greater in the mirtazapine group (−6.5 [95%CI; −8.3 to −4.8]) compared to the placebo group (−2.9 [95%CI; −4.4 to −1.4]), with a p-value of 0.003. No participant experienced severe adverse events. A total of 6 participants in the mirtazapine group and 1 participant in the placebo group discontinued their treatment due to adverse events. Conclusion: Mirtazapine reduces chronic insomnia symptoms in older people. However, its use may be limited by mild but clinically relevant adverse events. (clinicaltrials.gov NCT05247697). Impact statement: This is the first randomised, double-blind, placebo-controlled trial on the efficacy and safety of Mirtazapine in older adults with chronic insomnia. Our findings show that a 28-day treatment with mirtazapine, compared to placebo, significantly reduces insomnia severity, as measured by the Insomnia Severity Index. Despite the current lack of robust evidence, mirtazapine is widely prescribed by clinicians to treat insomnia in older adults with chronic insomnia. Publishing our study will facilitate the broad dissemination of this critical information, helping clinicians more effectively treat their older patients.